Study Title
CAMPFIRE: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma
Protocol ID
CAMPFIRE- J1S-MC-JP04
Condition/s
Ewing Sarcoma
Neoplasm Metastasis
Neoplasm Metastasis
Diagnosis Stage
Relapsed/refractory
Location
NSW, VIC
Sponsor
Eli Lilly and Company
Links
Trial Status
Closed to Recruitment
Sites
Royal Children's Hospital
The Children's Hospital at Westmead
Peter MacCallum Cancer Centre
The Children's Hospital at Westmead
Peter MacCallum Cancer Centre
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 39 Years
International registry ID's
NCT05440786
| Study Title | CAMPFIRE: A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma |
|---|---|
| Protocol ID | CAMPFIRE- J1S-MC-JP04 |
| Disease (Sub Disease) | Ewing Sarcoma Neoplasm Metastasis |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / VIC |
| Sponsor | Eli Lilly and Company |
| Links | https://clinicaltrials.gov/ct2/show/NCT05440786 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 10/09/2022 |
| Sites | Royal Children's Hospital / The Children's Hospital at Westmead/ Peter MacCallum Cancer Centre |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 39 Years |
| International registry ID's | NCT05440786 |